Lymphomas that are associated with the Epstein-Barr virus (EBV) are particularly frequent in patients with HIV/AIDS, organ transplants and other immunodeficiencies. In the HIV infection they represent an AIDS defining condition and typically present as a high grade, high stage malignancy, frequently involving extranodal sites including oral cavity. The EBV-associated lymphomas (EBV-AL) are rather heterogeneous in regard to the extent of expression of the EBV-encoded genes and, consequently, the apparent role EBV plays in their patogenesis. We have found that rapamycin and its derivative RAD [both act by selectively inhibiting a serine/threonine kinase called TOR or m(mammalian)TOR ], profoundly supress at low nanomolar doses the growth of cultured EBV-positive B-cells in vitro and in vivo (M. Majewski et al. 2000, M. Majewski et al., 2003). However, the exact mechanism of action of the TOR inhibitors on the lymphoma cells, the freqquency of TOR inhibitor sensitivity in various types of EBV-AL, and the putative role of EBV in induction of theTOR signaling remain to be elucidated. The studies proposed here will examine the mechanisms of TOR activation and and role of TOR and its, signaling pathwayin the pathogenesis of EBV-AL. Specifically, we will determine the: 1. activation status of the TOR signaling pathways in uncultured, patient-derived lymphoma cells 2. mechanisms of TOR activation in the lymphoma cells 3. role of TOR signaling in cell transformation of the lymphoma cells These studies may result in novel diagnostic and therapeutic approaches to the EBV-associated lymphomas in HIV/AIDS and other patients.

Agency
National Institute of Health (NIH)
Institute
National Institute of Dental & Craniofacial Research (NIDCR)
Type
Research Project (R01)
Project #
5R01DE017337-03
Application #
7231674
Study Section
Special Emphasis Panel (ZDE1-YL (13))
Program Officer
Rodriguez-Chavez, Isaac R
Project Start
2005-07-15
Project End
2008-05-31
Budget Start
2007-06-01
Budget End
2008-05-31
Support Year
3
Fiscal Year
2007
Total Cost
$263,002
Indirect Cost
Name
University of Pennsylvania
Department
Pathology
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Lioi, Anthony B; Ferrari, Brian M; Dubyak, George R et al. (2015) Human ? Defensin-3 Increases CD86 Expression on Monocytes by Activating the ATP-Gated Channel P2X7. J Immunol 195:4438-45
Lioi, Anthony B; Rodriguez, Angel L Reyes; Funderburg, Nicholas T et al. (2012) Membrane damage and repair in primary monocytes exposed to human ?-defensin-3. J Leukoc Biol 92:1083-91
El-Salem, Mouna; Raghunath, Puthiyaveettil N; Marzec, Michal et al. (2009) Activation of mTORC1 signaling pathway in AIDS-related lymphomas. Am J Pathol 175:817-24
Marzec, Michal; Liu, Xiaobin; Kasprzycka, Monika et al. (2008) IL-2- and IL-15-induced activation of the rapamycin-sensitive mTORC1 pathway in malignant CD4+ T lymphocytes. Blood 111:2181-9
Tsai, D E; Douglas, L; Andreadis, C et al. (2008) EBV PCR in the diagnosis and monitoring of posttransplant lymphoproliferative disorder: results of a two-arm prospective trial. Am J Transplant 8:1016-24
Marzec, M; Kasprzycka, M; Liu, X et al. (2007) Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway. Oncogene 26:5606-14
El-Salem, Mouna; Raghunath, Puthiyaveettil N; Marzec, Michal et al. (2007) Constitutive activation of mTOR signaling pathway in post-transplant lymphoproliferative disorders. Lab Invest 87:29-39